Core Viewpoint - Beida Pharmaceutical has entered into a strategic cooperation with Shengsi Bio to enhance its new drug innovation technology platform and expand its product pipeline [1] Group 1: Strategic Cooperation - The strategic cooperation framework agreement aims to leverage the strengths of both companies for mutual support and development [1] - Beida Pharmaceutical has signed a commercial cooperation agreement with Shengsi Bio, granting exclusive distribution rights for the product FRSW117 in the Greater China region [1] Group 2: Product Development - FRSW117 is a long-acting recombinant factor VIII product, classified as a type of therapeutic biological product, which has recently completed Phase III clinical trials [1] - The product is intended for routine prophylaxis, on-demand treatment, and perioperative bleeding management for hemophilia A patients, with a dosing frequency of once a week for preventive treatment [1] - Currently, there are no domestically approved long-acting recombinant factor VIII products available in the market [1]

Core Viewpoint - Beida Pharmaceutical has entered into a strategic cooperation with Jiangsu Shengsi Biopharmaceutical Co., Ltd. and Hangzhou Shengsi Biopharmaceutical Co., Ltd. to enhance its new drug innovation technology platform and expand its product pipeline [1] Group 1: Strategic Cooperation - The strategic cooperation aims to leverage the strengths of both parties to support mutual development [1] - A framework agreement has been signed to facilitate this collaboration [1] Group 2: Market Expansion - The partnership is focused on broadening the treatment areas and restructuring the blood product market [1] - This initiative is intended to better meet clinical needs and strengthen the company's product matrix [1] Group 3: Commercial Agreement - Beida Pharmaceutical has signed a commercial cooperation agreement with Hangzhou Shengsi Biopharmaceutical, granting exclusive distribution rights for the FRSW117 product in the Greater China region [1]